Showing 4119 results for "als"

Finding purpose in parenting with ALS

After my husband, Todd, was diagnosed with ALS at age 39, he grieved the loss of his career and struggled to find a sense of purpose. When he was healthy, he’d hoped to take on new roles with his company and advance in management, but all of that became…

ALS scholarship program to help students who have lost parents

The nonprofit organization ALS Northwest has partnered with the Oregon State Treasury to establish a college scholarship program through the state-administered Oregon College Savings Plan for students who have lost parents or guardians to amyotrophic lateral sclerosis (ALS). ALS Northwest will administer the Elinore Nudelman ALS College…

Eli Lilly to develop, market ALS therapy for UNC13A function

Eli Lilly has acquired the global exclusive rights to develop and market QRL-204, QurAlis’ investigational therapy for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) that’s designed to restore UNC13A function in nerve cells. UNC13A is an essential regulator of neurotransmitter release at synapses, a key process…

InnoVision to handle awareness campaigns for ALS Association

The ALS Association has selected InnoVision Marketing Group as its agency of record for creating media campaigns to raise awareness of amyotrophic lateral sclerosis (ALS) and the association’s mission of improving the lives of people with ALS. InnoVision, which has previously collaborated with the nonprofit on specific initiatives…

Qalsody approved in European Union to treat SOD1-ALS

The European Commission has approved Qalsody (tofersen) as a treatment for amyotrophic lateral sclerosis (ALS) associated with mutations in the SOD1 gene, known as SOD1-ALS. Qalsody was specifically granted marketing authorization under exceptional circumstances — a pathway recommended when the benefit-to-risk assessment for a therapy is favorable, but…